Drug intelligence / Profile preview

NOX-6-18

Development stage: Preclinical
Lead developer: Peking University
Modality: Small Molecules
Administration: Not Specified (preclinical Studies, Likely In Vivo Mouse Models)

Overview

NOX-6-18 is a **potent and selective small molecule antagonist of GPR132 (also known as G2A)**, with an IC50 of 17 nM. It has been shown in preclinical research to modulate macrophage reprogramming within pancreatic islets, decrease weight gain, and improve glucose metabolism in mice fed a high-fat diet. Structurally, it is described as 3-methyl-5-(N-phenethylsulfamoyl)benzofuran-2-carboxylic acid (CAS No. 898211-21-7) and has a molecular formula of C18H17NO5S and molecular weight of about 359.1 Da. NOX-6-18 is used as a research tool compound and is not approved for clinical or human use[1][4][7][10].

Other names: 3-methyl-5-(N-phenethylsulfamoyl)benzofuran-2-carboxylic acid

Targets

GPR132 (G protein-coupled receptor 132)

Beyond the preview

Go deeper on NOX-6-18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOX-6-18.

Explore the full profile